Drug intelligence / Profile preview

IMB-203

Development stage: Preclinical
Lead developer: Imbria Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

IMB-203 is an investigational **small-molecule succinate prodrug** being developed by **Imbria Pharmaceuticals** for **congenital metabolic disorders**, including **very long-chain acyl-coenzyme A dehydrogenase deficiency**. Available context describes it as an **SDH2 modulator** intended to augment mitochondrial metabolic function through succinate-related biology, with preclinical studies comparing oral IMB-203 to triheptanoin in VLCAD-deficient mouse models. The program appears to remain in **preclinical development**, and no marketed brand name has been identified.

Other names: succinate prodrug

Targets

SDHB (Succinate dehydrogenase iron-sulfur subunit)

Beyond the preview

Go deeper on IMB-203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMB-203.

Explore the full profile